**5. Conclusion**

A rapidly growing body of literature suggests that the IL-23/IL-17 axis is the major pathway that drives the chronic inflammation underlying psoriasis pathophysiology. The recent years have witnessed that superior clinical efficacy of IL-23/IL-17 pathway biologics in the systemic treatment of psoriasis brings to a major paradigm shift for the management of moderate-to-severe psoriasis. Nevertheless, lack of molecular targeted therapies remains for topical treatment of psoriasis.
